The costs and benefits of enhanced depression care to employers.

The costs and benefits of enhanced depression care to employers. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The costs and benefits of enhanced depression care to employers. Abstract Text:

Philip S Wang,Amanda Patrick,Jerry Avorn,Francisca Azocar,Evette Ludman,Joyce McCulloch,Gregory Simon,Ronald Kessler,

CONTEXT: Although outreach and enhanced treatment interventions improve depression outcomes, uptake has been poor in part because purchasers lack information on their return on investment. OBJECTIVE: To estimate the costs and benefits of enhanced depression care for workers from the societal and employer-purchaser perspectives. DESIGN: Cost-effectiveness and cost-benefit analyses using state-transition Markov models. Simulated movements between health states were based on probabilities drawn from the clinical literature. PARTICIPANTS: Hypothetical cohort of 40-year-old workers. Intervention Enhanced depression care consisting of a depression screen and care management for those depressed vs usual care. MAIN OUTCOME MEASURES: Our base-case cost-effectiveness analysis was from the societal perspective; costs and quality-adjusted life-years were used to compute the incremental cost-effectiveness of the intervention relative to usual care. A secondary cost-benefit analysis from the employer's perspective tracked monetary costs and monetary benefits accruing to employers during a 5-year time horizon. RESULTS: From the societal perspective, screening and depression care management for workers result in an incremental cost-effectiveness ratio of $19 976 per quality-adjusted life-year relative to usual care. These results are consistent with recent primary care effectiveness trials and within the range for medical interventions usually covered by employer-sponsored insurance. From the employer's perspective, enhanced depression care yields a net cumulative benefit of $2895 after 5 years. In 1-way and probabilistic sensitivity analyses, these findings were robust to a variety of assumptions. CONCLUSION: If these results can be replicated in effectiveness trials directly assessing effects on work outcomes, they suggest that enhanced treatment quality programs for depression are cost-beneficial to purchasers.

The costs and benefits of enhanced depression care to employers. Publishing Authors By Initials

PS Wang,A Patrick,J Avorn,F Azocar,E Ludman,J McCulloch,G Simon,R Kessler,

For similar income: salaries and fringe benefits research abstracts see: income: salaries and fringe benefits research

PUBMED ID PMID:

MEDLINE DATE:

The costs and benefits of enhanced depression care to employers. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Archives of general psychiatry

VOLUME: 63

Page Numbers: 1345-53

Journal Abbreviation: Arch. Gen. Psychiatry

ISSN: 0003-990X

DAY: 3

MONTH: Dec

YEAR: 2006

The costs and benefits of enhanced depression care to employers. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372435

The costs and benefits of enhanced depression care to employers. Keywords Mesh Terms:

KEYWORDS: Salaries and Fringe Benefits

MESH TERMS: statistics & numerical data

Chemical & Substance for Abstract: The costs and benefits of enhanced depression care to employers. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The costs and benefits of enhanced depression care to employers.

AFFILIATION: Department of Psychiatry, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, USA. wangphi@mail.nih.gov

Country: United States

AGENCY: United States NIMH

GRANT: R01 MH 61941

ACRONYM: MH

MEDLINETA: Arch Gen Psychiatry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The costs and benefits of enhanced depression care to employers Related Publications

• About the suboccipital part of the vertebral artery and the neighboring bone-joint and nerve relationships.
• Arthritis and physical-mental comorbidity in metropolitan China.
• Broadening the definition of generalized anxiety disorder: effects on prevalence and associations with other disorders in the National Comorbidity Survey Replication.
• Changes in surgical therapy for Crohn's disease over 33 years: a prospective longitudinal study.
• Clinical differences among patients treated for mental health problems in general medical and specialty mental health settings in the National Comorbidity Survey Replication.
• Complete robotic-assistance during laparoscopic living donor nephrectomies: an evaluation of 38 procedures at a single site.
• Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys.
• DSM-IV personality disorders in the National Comorbidity Survey Replication.
• Delay in initial treatment contact after first onset of mental disorders in metropolitan China.
• Developmental changes in progenitor cell responsiveness to bone morphogenetic proteins differentially modulate progressive CNS lineage fate.
• Developmental changes in progenitor cell responsiveness to cytokines.
• Dual function of Sox1 in telencephalic progenitor cells.
• FoxD3 and Grg4 physically interact to repress transcription and induce mesoderm in Xenopus.
• FoxD3 regulation of Nodal in the Spemann organizer is essential for Xenopus dorsal mesoderm development.
• Lifetime prevalence and inter-cohort variation in DSM-IV disorders in metropolitan China.
• Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: results from the National Comorbidity Survey Replication.
• Mental disorders among English-speaking Mexican immigrants to the US compared to a national sample of Mexicans.
• Mental health service use among hurricane Katrina survivors in the eight months after the disaster.
• Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
• Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior.
• Postcircumcision necrosis of the glans penis: gray-scale and color Doppler sonographic findings.
• Prevalence of the EH1 Groucho interaction motif in the metazoan Fox family of transcriptional regulators.
• Psychiatric epidemiology: challenges and opportunities.
• Risk for psychiatric disorder among immigrants and their US-born descendants: evidence from the National Comorbidity Survey Replication.
• Sonic hedgehog and BMP2 exert opposing actions on proliferation and differentiation of embryonic neural progenitor cells.
• Telephone screening, outreach, and care management for depressed workers and impact on clinical and work productivity outcomes: a randomized controlled trial.
• The costs and benefits of enhanced depression care to employers.
• The impact of comorbidity of mental and physical conditions on role disability in the US adult household population.
• The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication.
• Understanding mental health treatment in persons without mental diagnoses: results from the National Comorbidity Survey Replication.